Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-B4: Dapagliflozin + Metformin with Alpelisib in Advanced Breast Cancer
NCT04899349Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of dapagliflozin in hyperglycemia, sponsored by Novartis. Started Apr 2022; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT04899349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899349.